Syntheses and antifungal activities of novel 3-amido bearing pseudomycin analogues
Related Experiment Video
Updated: Oct 8, 2026

Production and Testing of Antimicrobial Peptides and Their Mimics
Published on: April 10, 2026
Y Z Zhang1, X Sun, D J Zeckner
1Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Abstract:
As a result of our core SAR effort, we discovered a large number of 3-amido pseudomycin B (PSB) analogues (e.g., 4e LY448212 and 5b LY448731) that retain good in vitro and in vivo (IP) activities against Candida and Cryptococcus without inherent tail vein irritation. Several dimethylamino termini bearing 3-amides (e.g., 5b) also exhibited improved potency against Aspergillus in vitro. When evaluated in a two-week rat toxicology study, it was found that all animals receiving 4e (up to 75 mg/kg) were found to be normal. On the basis of these observations, we are convinced that it is possible to broaden the antifungal spectrum and improve the safety profile of pseudomycin analogues at the same time.
Related Concept Videos
Antifungal Agents
Inhibitors of Bacterial Protein Synthesis
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Physical Properties of Amines
